Form 8-K · Current Report · Filed 2026-09-14
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
On September 14, 2026, DexCom, Inc. announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer (CFO). In this expanded role, Mr. Sylvain will assume oversight of Dexcom's global operations and quality teams, driving greater alignment, speed, and accountability across the company. Mr. Sylvain joined Dexcom in 2018 and has served as Executive Vice President and Chief Financial Officer since 2021. Throughout his tenure at Dexcom, Mr. Sylvain has built a strong finance leadership team and guided the company's journey of growth and margin expansion. Jake Leach, President and CEO, stated, 'Jereme is an exceptional leader and a valued strategic partner across Dexcom. His deep understanding of our business, operational discipline and customer focus make him the right leader for this expanded role. I am confident that Jereme will help us scale more effectively as we advance our goal to empower millions more people to take control of health.'
- Filer
- Dexcom Inc. DXCM · NASDAQ
- Filed
- Accession
- 0001093557-26-000175
- CIK
- 0001093557
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$83.03
Since filing
+0.0%
Latest close
$83.03
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from DXCM reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, DXCM insiders reported 15 Form 4 transactions — net selling of $4.1M.
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Never miss another DXCM filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.